[Webinar] Novel Design Strategies for Effective Next-Generation Nuclear Localization Signal (NLS)-Therapeutics
Title: Synthetic biology in biomedicine: engineered DNA- and RNA-encoded sensors Date: January 21, 2022, 10 AM EST (January 22, 2022, 12 AM KST)
Research on the implementation of nuclear localization signal (NLS)-therapeutics has been a topic of intense interest since the core principles governing nuclear transport were awarded the Nobel Prize in 1999.
Previously, Dr. Leyton's lab developed the compound Accum™ composed of NLS PKKKRKV from SV40 and linked to an endosomal membrane disruptive agent.
Accum-functionalized antibody-drug conjugates (ADCs) displayed improved tumor cytotoxicity, and commercialized vaccines revealed potent preclinical efficacy and will soon enter Phase 1 trials.
However, due to the non-specific cellular uptake of cationic NLSs, typical NLS-therapeutics is dependent on intravenous administration to clear rapidly from the bloodstream and reduce tumor uptake.
While NLS tagging can cause changes in nuclear transport pathways and impact nuclear localization efficiency.
In this technical session, Creative Biolabs has invited Dr. Leyton to describe the need to develop a more precise method in investigating nuclear transport dynamics of NLS-therapeutics.
Moreover, Dr. Leyton will also present a de novo approach for generating novel NLSs with an atypical zero net-charge and evaluating various strategies to determine the worth for integration into NLS-therapeutics development.
During this webinar, we will discuss the following key points:
• Why nuclear targeting improves drug efficacy • How nuclear transport functions • What are the significant challenges for pharmaceuticals targeting the nucleus
Jeffrey Leyton, Ph.D. Associate Professor Department of Nuclear Medicine and Radiobiology Faculty of Medicine and Health Sciences Université de Sherbrooke